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Salmonid cryptobiosis is caused by the haemoﬂagellate, Cryptobia salmositica. Clinical signs of the disease in salmon
(Oncorhynchus spp.) include exophthalmia, general oedema, abdominal distension with ascites, anaemia, and anorexia. The
disease-causing factor is a metalloprotease and the monoclonal antibody (mAb-001) against it is therapeutic. MAb-001 does not
ﬁx complement but agglutinates the parasite. Some brook charr, Salvelinus fontinalis cannot be infected (Cryptobia-resistant); this
resistance is controlled by a dominant Mendelian locus and is inherited. In Cryptobia-resistant charr the pathogen is lysed via the
Alternative Pathway of Complement Activation. However, some charr can be infected and they have high parasitaemias with no
disease (Cryptobia-tolerant). In infected Cryptobia-tolerant charr the metalloprotease is neutralized by a natural antiprotease,
α2 macroglobulin. Two vaccines have been developed. A single dose of the attenuated vaccine protects 100% of salmonids
(juveniles and adults) for at least 24 months. Complement ﬁxing antibody production and cell-mediated response in vaccinated
ﬁsh rise signiﬁcantly after challenge. Fish injected with the DNA vaccine initially have slight anaemias but they recover and have
agglutinating antibodies. On challenge, DNA-vaccinated ﬁsh have lower parasitaemias, delayed peak parasitaemias and faster
recoveries. Isometamidium chloride is therapeutic against the pathogen and its eﬀectiveness is increased after conjugation to
antibodies.
1.Introduction
Fish has been and will continue to be one of the major
sources of animal protein for humans. It will likely become
more important as the population heads towards 8 billion in
about 20 years as food production (e.g., growing of crops,
breeding of domestic animals) has and will continue to
compete with other human activities (e.g., transportation,
housing, industry) for the limited usable/inhabitable land.
Besides being a more aﬀordable animal protein many species
of marine ﬁshes have beneﬁcial health components which
include the polyunsaturated fatty acids (e.g., Omega 3).
However, the capture-ﬁshery is either stagnant or has been
in decline as natural ﬁsh stocks in many parts of the world
have been reduced signiﬁcantly because of over and/or
indiscriminate ﬁshing and/or the destruction of spawning
grounds. Many undesirable discharges (e.g., organophos-
phates, heavy metals) into the aquatic environments, espe-
cially from industries, are known to reduce ﬁsh survival
and reproduction. In some areas ﬁsh are no longer suitable
for human consumption because of the high levels of
accumulated pollutants, and no new ﬁshing grounds have
been discovered. According to the Food and Agriculture
Organization, aquaculture continues to be the fastest food
producing sector with about a 10% annual increase. It would
be higher if not for disease outbreaks [1]. Intensive culture
of freshwater and marine ﬁshes in cages is well developed in
many countries, especially in those that have large numbers
of rivers and lakes and/or long coastlines (e.g., China, Chile,
Norway). However, disease outbreaks become more frequent
as intensive ﬁsh culture tends to facilitate the transmission
of parasites between ﬁsh in cages and the acquisition of
pathogens from feral ﬁshes that are attracted to the uneaten
food in cages [2].
The piscine immune system is well developed, and in
many ways it is similar to that in mammals (e.g., [3])
which include a comparable set of immunocompetent cells
[4]. In general, the adaptive immune response is slower to2 Journal of Biomedicine and Biotechnology
Figure1:Cryptobiasalmositicawithredcellfromanexperimentally
infected rainbow trout (reproduced from Woo [5]).
develop in ﬁsh than in mammals, and this is in part due to
its lower body temperature. However, the innate immunity
i nﬁ s hi sa sw e l ld e v e l o p e da n di sa sr e s p o n s i v ea st h a t
in mammals. The present discussion is in two parts; the
ﬁrst part (Section 2) is a brief review on Cryptobia and
the pathobiology in cryptobiosis—information which are
relevant to the discussion on the development of strategies
against the pathogen and disease (Section 3).
2.Cryptobia salmositica andCryptobiosis
2.1. The Parasite. Cryptobia is a parasitic ﬂagellate that has
worldwidedistribution,andafewspeciesareknowntocause
disease in marine and freshwater ﬁshes. This extracellular
parasite is elongated and is a little larger than a ﬁsh red
blood cell. Its nucleus is close to the kinetoplast which is
located at the anterior end. The parasite has an anterior
ﬂagellum and a recurrent ﬂagellum that attaches to the
body and exit as a free ﬂagellum at the posterior end
[5].
Salmonid cryptobiosis is caused by the haemoﬂagellate
Cryptobia (Trypanoplasma) salmositica (Figure 1). The
pathogen has been reported in all species of Paciﬁc salmon,
Oncorhynchus spp., along the west coast of North America
[5], and outbreaks of cryptobiosis with high ﬁsh mortalities
have occurred in both freshwater hatcheries and in sea
cage cultures [6]. The parasite multiplies by binary ﬁssion,
and the parasitaemia peaks at about 4-5 weeks after
infection (e.g., [7–9]). The severity of the disease (e.g.,
the anaemia) is directly related to the parasitaemia and
clinical signs include exophthalmia (Figure 2), general
oedema, abdominal distension with ascites, a microcytic
and hypochromic anaemia, positive antiglobulin reaction
(or positive Coombs’ test) of red cells (Figure 3), and
anorexia [7, 10, 11]. Anorexia is a double-edged sword—it
is beneﬁcial to the host in that it reduces the severity of the
disease by lowering plasma proteins and subsequently the
parasitaemia but it is also detrimental to the ﬁsh in that it
contributes to the immunodepression [11, 12]. During acute
diseasethehaemolyticactivityofcomplementissigniﬁcantly
lowered [13]. In addition, plasma thyroxine (T3 and T4),
Figure 2: Exophthalmia in rainbow trout with an acute experimen-
tal cryptobiosis (reproduced from Woo [5]).
Figure 3: Positive antiglobulin reaction; red blood cells from an
experimentally infected rainbow trout (reproduced from Woo [5]).
protein, and glucose are reduced along with depletion
of liver glycogen [14]. The metabolism and swimming
performance of infected rainbow trout are also signiﬁcantly
reduced [15], and the bioenergetic cost of the disease in
juvenile ﬁsh is considerable. These are contributing factors
to the retarded growth as there are signiﬁcant reductions
in food consumption, dry weight and energy gained,
energy concentration, and gross conversion eﬃciency.
However, the attenuated vaccine strain (Section 3.3.1)
has no detectable bioenergetic cost to juvenile ﬁsh
[16].
2.2. A Cysteine Protease and a Metalloprotease. Two proteases
have been identiﬁed in the pathogen [17]. The cysteine
protease consisting of four polypeptide bands (49, 60, 66,
and97kDa)isametabolic enzymewhilethemetalloprotease
(200kDa) is a histolytic enzyme. The metalloprotease has
been isolated and puriﬁed (Figure 4). Its proteolytic activity
is inhibited by excess of zinc ions [17–19]. The puriﬁed
enzyme lyses red blood cells [20] by digesting erythrocyte
membranes[18].Consequently,itisanimportantcontribut-
ing factor to the anaemia which is a very consistent clinical
sign of the disease. Also, the puriﬁed metalloprotease readily
degrades types I, IV, and V collagens (Figure 5) and laminin
[18]. It is secreted by the parasite in ﬁsh [21] and in culture
[19], and it contributes signiﬁcantly to the developmentJournal of Biomedicine and Biotechnology 3
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Figure 4: Puriﬁcation of cysteine protease and metalloprotease
from Cryptobia salmositica. Lane A: crude cell lysate; lane B:
partially puriﬁed cysteine protease from a DEAE-agarose column;
lane C: partially puriﬁed metalloprotease from a DEAE-agarose
column; lane D: a single band of puriﬁed metalloprotease from
a Sephacryl S-300 column; lane M: molecular markers (kDa)
(reproduced from Zuo & Woo [18]).
of the disease and histopathogical lesions in infected ﬁsh
[22].
Brieﬂy, metalloprotease activities can be neutralized by
either a monoclonal antibody (Section 3.1)o ran a t u r a l
antiprotease (Section 3.2.2) or the antibody against the DNA
vaccine (Section 3.3.2); this neutralization essentially “dis-
arms” the pathogen so that the host immune system can
more readily control the infection.
3.StrategiesagainstCryptobia
andCryptobiosis
3.1.Serological. AmurineIgG1monoclonalantibody(mAb-
001; Figure 6) has been produced against the 200kDa
glycoprotein (Cs-gp200). The antibody is therapeutic when
injected intraperitoneally into infected ﬁsh—it signiﬁcantly
lowers the parasitaemias in ﬁsh and this is similar to the
eﬀects of the inoculation of antisera from ﬁsh that had
recoveredfromcryptobiosis.Also,mAb-001hasprophylactic
eﬀects in ﬁsh [23]; however, it does not ﬁx complement but
agglutinates live parasite. In vitro exposure of the parasite to
mAb-001reducesitssurvivalandinfectivitywheninoculated
back into ﬁsh [24]. The monoclonal antibody also inhibits
parasite multiplication and its aerobic respiration [25], and
it completely neutralizes the activity of the metalloprotease
[26]. The Cs-gp200 epitope consists of carbohydrate deter-
minantsandconformationalpolypeptidewithinternaldisul-
phide bonds. It is hydrophilic and is secreted by the parasite
[27]. The epitope has its asparagine-bound N-glycosidically
linked hybrid-type carbohydrate chain with the minimum
length of a chitobiose core unit. It has a phosphatidylinositol
residue which anchors the conformational polypeptide (with
disulphide bonds) to the surface of the pathogen. The
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Figure 5: In vitro proteolytic degradation of collagen type V by
puriﬁed metalloprotease from Cryptobia salmositica. Lanes A–E:
collagen incubated with metalloprotease for 0, 2, 4, 6, and 8 hours
respectively; lane F: collagen incubated under same conditions
as lanes A–E, but without metalloprotease (control); lane M:
molecular markers (reproduced from Zuo and Woo [18]).
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Figure 6: Immunoblot using mAb-001 on Cryptobia salmosit-
ica lysate. Lane A: mAb-001 after immunoabsorption with live
parasites; lane B: mAb-001 without immunoabsorption; lane C:
hybridoma culture medium. The numbers on the left are molecular
mass (kDa) of protein standards.
moleculeisextensivelyposttranslationallymodiﬁed[28],has
high mannose components, and appears as a doublet in
the pathogenic strain and as a single band in the attenuated
vaccine strain [29].
3.2. Innate (Natural) Immunity. In the present discussion,
a distinction is made to distinguish between the two forms
of natural immunity—the ﬁrst is absence of disease in
an infected ﬁsh (pathogen-tolerant ﬁsh) and the second is
resistance to infection by a ﬁsh (pathogen-resistant ﬁsh).
3.2.1. Cryptobia-Resistant Fish. Some laboratory/hatchery
raised brook charr, Salvelinus fontinalis, cannot be infected4 Journal of Biomedicine and Biotechnology
with C. salmositica, and this is innate resistance to
infection. Resistance to Cryptobia infection is inherited
by progeny and it is controlled by a single dominant
Mendelian locus. Cryptobia-susceptible brook charr are
homozygous recessive while the Cryptobia-resistant ﬁsh
are either homozygous or heterozygous dominant for the
locus [30]. Consequently, we can now breed resistant ﬁsh
by initially testing the freshly collected plasma from the
brood ﬁsh for cryptobiacidal eﬀects. Brieﬂy, under in vitro
conditions fresh plasma from Cryptobia-resistant charr lyse
the parasite via the Alternative Pathway of Complement
Activation [31] .T h e r ei sn od e t e c t a b l ed i ﬀerence in the
immuneresponsesofbothCryptobia-tolerant(Section 3.2.2)
and Cryptobia-resistant charr to other antigenic stimu-
lations including a commercial vaccine [32]. Not much
is known about this type of resistance and its inheri-
tance by progeny; consequently, further studies on innate
resistance to infections in other animals would be most
rewarding because it can be a good strategy against some
pathogens.
3.2.2. Cryptobia-Tolerant Fish. Parasitaemias in some
infectedbrookcharrarejustashighasthoseinOncorhynchus
spp.; however they do not suﬀer from cryptobiosis
(Cryptobia-tolerant ﬁsh). Cryptobia-tolerant brook charr are
resistance to disease because the metalloprotease secreted
by C. salmositica is neutralized by the α2m a c r o g l o b u l i n
(a natural antiprotease) in the blood. The amount of α2
macroglobulin is higher in brook charr than in rainbow
trout prior to infection and it remains high (about 40%)
even at peak parasitaemia while that in trout drops to about
12% [21, 33]. Parasitaemias in both infected rainbow trout
and brook charr peak at about 4–6 weeks after infection
and as antibodies are produced the parasitaemias decline;
however, the parasitaemia ﬂuctuates in rainbow trout
while that in infected Cryptobia-tolerant charr rapidly
declines after peak parasitaemia [32]. Neutralization of the
metalloprotease by α2 macroglobulin was demonstrated
under both in vivo and in vitro conditions [18, 21, 33]. Since
Cryptobia-tolerant charr do not suﬀer from clinical disease,
the immune system readily controls the infection and the
ﬁsh recover much more rapidly than trout from the infection
[32].
An obviously option to control cryptobiosis in salmon
is to consider producing transgenic Cryptobia-tolerant
salmonids. It is expected that the transgenic salmon will
maintain high levels of α2 macroglobulin in their blood,
essentially to neutralize the metalloprotease secreted by the
pathogen—the additional α2 macroglobulin will eliminate
or at least reduce the severity of the disease. Since the
disease is absent or less severe, the ﬁsh immune system
can more eﬀectively control the infection. This proposal
is a novel approach to the management of an infectious
disease in animals and it perhaps needs further discussions.
An obvious “downside” with this approach is that it may
increase the pool of reservoir animals (with infections but no
disease) in the population but one very obvious advantage
is that no further human interventions (e.g., vaccination,
chemotherapy) are required once the transgenic animal is
produced.
3.3. Adaptive (Acquired) Immunity. Adaptive immunity has
also been exploited to protect the susceptible Oncorhynchus
spp. from cryptobiosis. Two distinctly diﬀerent experimental
vaccines (a live attenuated vaccine and a metalloprotease-
DNA vaccine) have been developed. Fish inoculated with
the live attenuated Cryptobia vaccine are protected from
infection when challenged with the parasite. However, the
metalloprotease-DNA vaccine does not prevent an infection
in vaccinated ﬁsh but antibodies produced in the vaccinated
ﬁsh neutralize the disease-causing factor secreted by the
pathogen. Although the DNA-vaccinated ﬁsh is infected,
it does not suﬀer from cryptobiosis, and it essentially
turns the pathogenic Cryptobia into a nonpathogenic ﬂag-
ellate as in the case of the Cryptobia-tolerant brook charr
(Section 3.2.2).
3.3.1. Live Vaccine. C. salmositica was attenuated by pro-
longed in vitro culture and the strain has been cloned. The
attenuated parasite is maintained in tissue culture medium
and it has remained avirulent since 1990. It produces a low
infection in rainbow trout, does not cause disease, circulates
in the blood for at least 6 months, and is protective when
the ﬁsh is challenged with the pathogen [34]. The vaccine
strain is smaller in size and has lost a few polypeptides. It
is adapted to in vitro culture and hence multiplies much
more readily than the pathogenic strain in tissue culture
medium [35, 36]. A single injection of the strain protects
100% of vaccinated ﬁsh and consequently it is used routinely
as an experimental vaccine to study the development and
mechanism of protective immunity in salmonids and the
pathobiology of the disease. The vaccine has no detectable
bioenergetic cost to juvenile rainbow trout [16], and it
protects various species of juvenile and adult salmonids from
the pathogen (e.g., [8, 9, 37–41]).
Rainbow trout vaccinated in fresh water and transferred
to sea water are also protected on parasite challenge [42].
A single dose of the vaccine protects rainbow trout for at
least 24 months [8]. Vaccinated ﬁsh are partially protected
if they are challenged at 2 weeks postvaccination (wpv)
while all vaccinated ﬁsh are protected (e.g., no drop in
packed cell volume and virtually no detectable infection
after parasite challenge) at 4wpv. Protection is via the
production of complement ﬁxing antibodies and under in
vitro conditions activated macrophages from head kidneys
ofvaccinatedﬁshshowantibody-independentandantibody-
dependent cytotoxicities. Also, in the presence of antiserum
macrophages are very eﬃcient in engulﬁng living parasites
(Figure 7).
The complement ﬁxing antibody titres (e.g., [8]) and
cell-mediated response (e.g., [40]) in vaccinated ﬁsh rise
signiﬁcantlysoonafterparasitechallenge(classicalsecondary
responses), and the responses in vaccinated and challenged
ﬁsh are similar to those in na¨ ıve ﬁsh at 6 weeks after infec-
tion. Humoral and cell-mediated immunity are importantJournal of Biomedicine and Biotechnology 5
Figure 7: Peritoneal macrophage in the ascites of an experimentally
infected rainbow trout, Cryptobia salmositica in the process of being
ingested (reproduced from Woo [7]).
components of the protection against C. salmositica in both
vaccinated and recovered ﬁsh (e.g., [8, 9, 40, 43]).
3.3.2. Metalloprotease-DNA Vaccine. As indicated earlier
(Sections 3.1 and 3.2.2) the disease causing metalloprotease
(200kDa glycoprotein) can be neutralized. This is accom-
plished either by the α2 macroglobulin (a natural antipro-
tease) in Cryptobia-tolerant brook charr [18, 21, 33]w h e r e
the parasitaemia does not ﬂuctuate and the ﬁsh recovers
rapidly [32] or by an antibody (mAb-001) produced against
the 200kDa glycoprotein [26]. The monoclonal antibody
(mAb-001) agglutinates the parasite and reduces its survival
and infectivity [24]. Neutralization of the metalloprotease by
antibodies in vaccinated ﬁsh is the basis of our current DNA
vaccine.
Brieﬂy, the metalloprotease and cysteine protease genes
of C. salmositica were sequenced [45, 46] and inserted into
plasmid vectors (pEGFP-N) to produce a metalloprotease-
plasmid vaccine and a cysteine-plasmid vaccine [47]. Rain-
bow trout and Atlantic salmon, Salmo salar, injected intra-
muscularlywiththemetalloprotease-plasmidvaccineconsis-
tently had lower packed cell volume (as metalloprotease was
secreted into the blood) than controls (ﬁsh inoculated either
with plasmid alone or with cysteine-plasmid vaccine) at 2–
4wpv. However, the packed cell volume in metalloprotease-
vaccinated ﬁsh returned to normal by 5wpv—this was
because the metalloprotease was neutralized as antibodies
were produced. Agglutinating antibodies against C. salmosit-
ica were detected 5–7wpv in the blood (and not before
5wpv) in metalloprotease-vaccinated ﬁsh, but not in ﬁsh
injected with either the cysteine-plasmid or plasmid alone
injected ﬁsh. Fish were challenged with the pathogen at
7wpv and the metalloprotease-vaccinated ﬁsh had lower
parasitaemia, delayed peak parasitaemia, and faster recovery
than control infected ﬁsh. In a recent review on the
use of DNA vaccines in aquatic organisms Kurath [48]
conﬁrms that this is the “...ﬁrst published demonstration
of protective eﬀects of a ﬁsh parasite DNA vaccine in ﬁsh.”
Many protozoa that are of medical and economic
importance (e.g., Trypanosoma spp., Leishmania spp.) have
metalloprotease and cysteine protease [49]. Some of these
pathogens also modify their surface coats to evade the
host immune response (e.g., antigenic variations as in the
Glossina-transmitted mammalian trypanosomes in Africa);
consequently vaccines based on surface membrane epitopes
are not eﬀective. However, an enzyme-based vaccine may be
worth serious considerations as enzymes are quite conserve.
Also, an enzyme-based vaccine will most likely protect
against all isolates of the pathogen including those from
diﬀerent geographical locations which may have diﬀerent
surface membrane antigens. Enzymes are generally quite
conserve and this is true even among diﬀerent pathogens;
for example, sequences of PCR-derived fragments of the
m e t a l l o p r o t e a s eg e n eo fC. salmositica [45] are similar to
those in other kinetoplastids, such as Leishmania chagasi,
L. donovani [50], Trypanosoma cruzi [51], and T. brucei
[52]. Major surface protease (MSP) also known as GP63
or leishmanolysin is a highly abundant zinc metalloprotease
present on the cell surface of Leishmania spp. The NCBI-
conserved domain search shows that the alignment for the
metalloprotease of C. salmositica has 78.3% similarity with
peptidase M8, leishmanolysin domain [45].
3.4. Chemotherapy and Immunochemotherapy. Chemother-
apy is essentially diﬀerential toxicity; that is, the drug is
more toxic to the target organism than it is to the host.
Severity of the side eﬀects of chemotherapy is dependent
partly on tissue damage and adverse reactions by the host to
thedrug.However,thedrugcanbedirectedmorespeciﬁcally
to the pathogen if it is conjugated to an antibody speciﬁc for
the target organism. Immunochemotherapy will obviously
increase costs and is generally not meant for routine use; it
may however be a useful tool under certain circumstances as
it reduces the drug dosage and its side eﬀects. For example,
it can be used to treat infected brood ﬁsh as about 50% of
brood ﬁsh annually die from cryptobiosis in some hatcheries
on the west coast of North America [6]. It is expected the
side eﬀects and accumulation of drug residues in host tissues
will be reduced in immunochemotherapy, and this may also
lower the risk of the development of drug-resistance by
the pathogen. Reduction in drug residue in host tissues is
also an important consideration if the ﬁsh are for human
consumption.
3.4.1. Chemotherapy. In tropical Africa isometamidium
chloride (Samorin) is widely used against trypanosomiasis
in domestic animals [53], and it is also used as a prophylactic
drug against bovine trypanosomiasis [54]. In ﬁsh, Samorin
(1.0mg/kg weight) reaches peak level in the blood 2-3 weeks
after intramuscular injection [55]. The drug is therapeutic
against C. salmositica in rainbow trout during pre- and post-
clinical phases of the disease. However, it is not eﬀective
during acute disease partly as we believe that the drug
“modiﬁes” surface epitopes of the parasite so that they
are not lysed by complement ﬁxing antibodies [56]. The
drug is more eﬀective in infected Atlantic salmon, and
at a higher dose (2.5mg/kg) the infection is eliminated
in about 30% of adult ﬁsh and signiﬁcantly reduces the
parasitaemias in remaining ﬁsh. Also all infected juvenile
chinook salmon, Oncorhynchus tshawytscha, treated with
isometamidium chloride (1.0mg/kg) survived the disease6 Journal of Biomedicine and Biotechnology
Table 1: Infectivity of Cryptobia salmositica to chinook salmon after in vitro exposure to isometamidium chloride to polyclonal antibodies
from a recovered ﬁsh (reproduced from Ardelli and Woo [59]).
Weeks
After
Infection
Group 1 Group 2 Group 3 Group 4 Group 5
PAlC Drug PAl Antibody Untreated Controls
1 1/10 ￿ 7/10 0/10 0/10 8/10
0.30 ±0.95  1.80 ±2.78 0 0 6.60 ±4.72
2 1/10 6/10 2/10 0/10 10/10
0.30 ±0.95 8.10 ±5.28 1.80 ±3.91 0 48,750 ±45,814
3 2/10 7/10 2/10 0/10 10/10
0.50 ±1.27 33,250 ±38,207 1,950 ±4,310 0 35,625 ±29,978
4 2/10 8/10 3/10 3/10 10/10
0.30 ±0.675 302,000 ±254,142 2,500 ±5,270 5,558 ±16,665 5,487,500 ±5,439,838
5 2/10 10/10 4/10 4/10 10/10
0.60 ±1.58 9,395,000 ±16,925,911 54,740 ±112,499 556,944 ±1,500,001 3,175,000 ±3,639,196
6 1/10 10/10 4/10 4/10 10/10
3,750 ±11,858 13,475,000 ±15,298,624 503,750 ±1,030,810 2,600,000 ±5,577,465 3,243,750 ±5,416,196
7 1/10 10/10 4/10 4/10 10/10
11,250 ±35,575 18,305,000 ±52,500,000 928,860 ±1,326,575 44,383,334 ±129,150,260 27,051,250 ±56,209,714
￿ Number of infected ﬁsh/number of ﬁsh inoculated.
Mean parasitaemia ± standard deviation, determined by HCT or haemacytometer.
while 100% of untreated infected ﬁsh died with massive
parasitaemias. The drug also has prophylactic value, and it
doesnotseemtoaﬀectﬁshgrowth,foodconsumption,blood
complement levels, or haematocrit values in ﬁsh [57].
Samorin accumulates rapidly in the kinetoplast of
the parasite [44], causes condensation of its kineto-
plast DNA, forms vacuoles, and swells the mitochondrial
cristae (Figure 8). Although the parasite normally undergoes
aerobic respiration [25], it also has glycolytic enzymes
sequestered in microbodies called glycosomes [58]. The in
vitro oxygen consumption and carbon dioxide production
decrease signiﬁcantly after drug exposure with very signiﬁ-
cant increases in secretion of glycolytic products (lactate and
pyruvate) as the parasite switches from aerobic respiration
to glycolysis after its mitochondrion is damaged by the drug
[44]. Also, in vitro exposure to sublethal levels of the drug
reduces infectivity of the parasite to ﬁsh and changes the
surface glycoprotein antibody-receptor sites of the parasite.
This alteration of surface epitopes explains the protection of
some parasites from lysis by complement ﬁxing antibodies
when rainbow trout with acute infections were treated with
the drug [56].
3.4.2. Immunochemotherapy. Ardelli and Woo [59]c o n -
jugated isometamidium chloride to polyclonal antibodies
(from“recovered” ﬁsh) and the monoclonal antibody (mAb-
001, Section 3.1). The conjugated drug is on the entire
parasitewhiletheunconjugateddrugaccumulatesonlyinthe
kinetoplast (Figure 9). Before drug conjugation both anti-
bodies agglutinate living parasites but they react diﬀerently
after drug conjugation. Polyclonal antibodies-conjugated
drug(PAIC)lysesmostoftheparasiteanditnolongeragglu-
tinatestheparasite.Incontrast,themAb-00-conjugateddrug
does not lyse C. salmositica but agglutinates it. After in vitro
(a)
(b)
(d)
(c) (e)
0.25μm
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Figure 8: Ultrastructural lesions in Cryptobia salmositica after in
vitro exposure to isometamidium chloride. (a) Parasite kinetoplast
(K) not exposed to the drug; (b) condensation of kinetoplast
DNA after exposure to the drug; (c) vacuole (V) formation after
drug exposure; (d) swelling of mitochondrial cristae (C) after drug
exposure; (e) vacuole formation in cytoplasm after drug exposure
(reproduced from Ardelli and Woo [44]).
exposure to PAIC the infectivity of the parasite and sub-
sequent parasitaemias in inoculated ﬁsh were signiﬁcantlyJournal of Biomedicine and Biotechnology 7
(a) (b)
Figure 9: Phase contrast and ﬂuorescent microscopy of Cryptobia
salmositicaafterexposuretoisometamidiumchloride.(a):Exposure
to drug only, note accumulation of drug (in red) in the kinetoplast;
(b): exposure to drug conjugated to polyclonal antibodies from
a recovered ﬁsh, note that the drug (in red) is throughout the
organism (reproduced from Ardelli and Woo [59]).
lowered. Fish survival (Table 1) was much higher in juvenile
chinook salmon infected with parasites exposed to the
polyclonal antibodies-conjugated drug (PAIC) than to drug
alone (Drug) or to polyclonal antibodies alone (Antibody)
or to drug plus polyclonal antibody (PAI). Also, preliminary
studies indicate the drug-antibody conjugate to be eﬀective
when injected into infected ﬁsh. The results are encouraging
and further studies are needed, for example, to determine
dosages needed, reﬁnement of the approach (e.g., stage of
infection, species of salmonids).
4. Conclusions
Our concerted eﬀorts to better understand the biology of
Cryptobia and the mechanism of the disease have allowed
us to develop more rational strategies against the pathogen
and disease. We have been relatively successful in exploiting
the piscine immune system to protect salmonids against C.
salmositica and cryptobiosis. This is an ongoing and evolving
research program and there is obviously a great deal of work
that needs to be conducted. However, I hope our research
willbeofinterestandperhapsbeusefultocolleagueswhoare
also developing control measures against similar pathogenic
organisms. The research has been both challenging and
fascinating, and I would like to think the best is yet to come.
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